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ABSTRACT
Background: Many individuals with type 2
diabetes in emerging countries are
transitioning from vial-and-syringe insulin
delivery to that of insulin pens (disposable or
reusable). As with all insulin delivery methods,
patient preferences and comfort are of utmost
importance to optimize adherence to
treatment. Patient-preferred characteristics for
reusable insulin pens and barriers to appropriate
injection, particularly in these regions, have not
been widely reported in the clinical literature,
highlighting a key information gap for
clinicians considering these methods as part of
a comprehensive diabetes management
approach.
Methods: Face-to-face interviews were
conducted with people with type 1/2 diabetes,
including insulin-naı¨ve and established insulin
users. After moderator demonstration,
participants were evaluated on their ability to
perform a six-step process to inject a 10-unit
dose into a pad with the AllStar (AS; Sanofi,
Mumbai, India), HumaPen Ergo II (HE2; Eli
Lilly, Indianapolis, USA), and NovoPen 4 (NP4;
Novo Nordisk, Bagsværd, Denmark) pens. Local
pens were also tested in India, China and Brazil.
Results: A total of 503 people from India,
Malaysia, Brazil, Egypt, and China
participated. Participants completed the six-
step process in an average, 2–3 min per pen.
Participants ranked ease of overall use and ease
of self-injection and dialing/reading dose as
most important features for new insulin pens.
When using the pens, the most difficult step
was priming/safety testing, with 7–12% failing
and 28–40% having difficulty; 6%, 18%, and
22% failed to hold the injection button down
for the required period of time using AS, NP4,
and HE2, respectively. Participants ranked AS
significantly higher for nine of 12 ease-of-use
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features including three of the top four features
considered the most important for reusable
pens, while HE2 was ranked higher for two
features. Local pens were ranked lowest.
Conclusions: Priming the pen and injecting
the dose imparted most difficulty for people
with diabetes in emerging countries. Most
participants found AS easiest to use overall,
with differences noted between pens for
individual steps of dose delivery. Identifying
characteristics most preferred by patients may
assist in improving adherence to insulin
therapy.
Keywords: AllStar; Diabetes; HumaPen;
Insulin; Insulin pens; NovoPen
INTRODUCTION
The prevalence of diabetes is high in emerging
countries or regions such as Brazil, India, China,
the Middle East, and Southeast Asia and is
expected to increase at least twofold in the next
20 years [1]. Most people with diabetes have
type 2 diabetes mellitus (T2DM) and are initially
treated with lifestyle changes and oral
antidiabetic drugs [2]. However, because of the
progressive nature of the disorder, many will
need insulin to achieve glycemic control and
thus, the use of insulin-based regimens is
expected to continue to increase.
Some of the barriers to insulin use stem from
the perceived discomfort and fear of insulin
injections; these have been addressed by the
introduction of insulin pens as a delivery
mechanism [3]. Insulin pen design has focused
on a combination of patient convenience/
satisfaction and affordability. This is especially
important in emerging countries where the
need for affordable, convenient insulin
delivery is readily apparent. As patient
awareness of insulin pens increases in
emerging countries, it is important to identify
those insulin pen characteristics that are most
vital to optimizing patient acceptance and
adherence. The aim of this market research
survey is provide insight from people with
diabetes in emerging countries into the usage
characteristics of three to four different reusable
insulin pens available in their respective




Individuals with type 1 diabetes mellitus
(T1DM) or T2DM were recruited for a market
research survey in Brazil, China, Egypt, India,
and Malaysia by various methods, including
street intercept, snowball sampling (i.e.,
identifying one or more participants in the
desired population and using them to find
further participants), and recommendation by
a healthcare professional. A mixture of gender,
occupations, and insulin-naı¨ve or insulin-
experienced individuals were recruited. If
patients were insulin naı¨ve, they must have
discussed starting insulin with their physician
and must be willing to do so in the future,
otherwise they were excluded from the study.
People were also excluded if they had
participated in diabetes market research in the
past 3 months.
Patient Interviews
Face-to-face interviews were conducted in the
local language in either the participant’s home
or a central location. Interviews were conducted
from June to August 2013 by experienced
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moderators fully briefed on the research
survey’s objectives and materials (pens,
cartridges, needles, instruction manuals), and
the interview was recorded. After the
interviewer confirmed information about the
participant, each individual was given a
shuffled deck of 12 cards, each showing a
feature that could relate to a device for
injecting a medicine for diabetes. The 12 key
features were confirmed in a pilot phase
consisting of 2 days of centrally viewed
interviews in each market conducted earlier in
May 2013. The participants were asked to put
the 12 cards in order of importance to them.
Each rank was assigned its corresponding
numerical value (i.e., 1.0 for most important,
2.0 for second most important, and so on). For
the entire group, the rankings were then
averaged to determine the most important
characteristics, with importance ranked from
lowest to highest value.
The moderator then demonstrated the use of
one of the devices, and the participants were
asked to prepare the device and inject a 10-unit
dose into a pad. This was repeated for each
available device, and a manual in the local
language was provided for each pen for
reference. For each pen, participants were
evaluated on their ability to (1) remove the
cap, unscrew the cartridge holder and insert the
cartridge; (2) screw/lock the cartridge holder; (3)
attach the needle; (4) prime/safety test the
device; (5) dial the dose; and (6) deliver the
dose. The AllStar (AS; Sanofi, Mumbai, India),
NovoPen 4 (NP4; Novo Nordisk, Bagsværd,
Denmark), and HumaPen Ergo II (HE2; Eli
Lilly, Indianapolis, USA) were tested in all
markets; in addition, one local pen was tested
in India (INSUPen; Biocon, Bangalore, India),
Brazil (HumaPen LuxuraTM; Eli Lilly, Sao
Paulo, Brazil), and China (Xuilin Pen; Gan &
Lee, Beijing, China). The order of presentation
of the devices was randomized via three-way or
four-way randomization (based on number of
pens tested) so that a particular pen was not
always first and two pens did not always follow
one another. In all countries, participants were
not tested on a device that they had used or
were currently using, except in Malaysia. NP4
was tested by a sub-sample of current users in
Malaysia (n = 52), where the pen is provided
free of charge by the government.
The participants were next asked to compare
each device across 12 key features by answering
a series of questions (Table 1). They were asked
to choose which pen was the best and worst for
each of those features. Finally, they were asked
which device was easiest to use overall, and
which device was their last choice. For each
question, participants in Brazil, China, and
India were also asked to name their second
choice, after naming their first choice, before
naming their last choice. The results were
tabulated and data were tested at the 95%
significance level, using z tests and t tests (as
appropriate) to establish significance between
means and proportions, respectively. Data were
analyzed using QPSMR CL (version 2011.2,
NetMR Ltd., Cupar, Fife, Scotland, UK) and
DigitabXL (version 12.0, Digitab, London, UK).
As a market research survey, analyses herein
do not fall under the auspices of the ethical
standards on human experimentation
(institutional and national) and the Helsinki
Declaration of 1975 (revised 2000, 2008).
Consent was gained from all patients for their
participation in the demonstration of injection
devices (following instructions from the
moderators and presentation of instruction
manuals) for the data to be reported at an
aggregate level; patients were also informed
about adverse events reporting procedures.
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RESULTS
Patients
A total of 503 participants from India, Malaysia,
Brazil, Egypt, and China were interviewed
(Table 2). The participants were equally
divided between those who were either insulin
naı¨ve (49%) or insulin users (51%). More of the
insulin users had T2DM (58%) than had T1DM
(42%) due to only a few of the insulin users in
Malaysia having T1DM (13%). In the other four
countries, insulin users were equally divided
between those with T1DM and those with
T2DM.
Ease of Use of Pens
Participants completed the preparation and
dose injection process with AS, NP4, or HE2 in
an average of 2–3 min (Fig. 1), with no
significant differences between insulin-naı¨ve
participants and insulin users. There were
differences between the pens for individual
steps. For removing the cap, unscrewing the
cartridge holder, and inserting the cartridge
(Step 1), 20% of participants struggled to
remove the cartridge holder from NP4 due to
its stiffness or to trying to pull the cartridge
holder out rather than unscrew it; with HE2, 5%
of participants tried to twist the cap off and 2%
had difficulty inserting the cartridge; with AS,
2% had difficulty inserting the cartridge into
the pen/holder (e.g., inserting cartridge upside
down). Three percent of participants using AS
and 6% using NP4 struggled to position the
cartridge holder correctly (Step 2), while 5%
with HE2 had some difficulty with this step
because of the stiff cartridge holder. Help to
attach the needle (Step 3) was needed for 2% of
Table 1 Questionnaire: comparison of devices
1. Which device is easiest for you to inject yourself? Which is hardest?
2. Which device is easiest for you to dial the right dose? Which is hardest?
3. Which device is easiest for you to read the dose? Which is hardest?
4. Which device do you think is the best if you needed to inject a high dose (e.g., 80 units)? Which is worst?
5. Which device is easiest for you to see how much insulin is in the cartridge? Which is hardest?
6. Which device is easiest in terms of feeling the dial turn and hearing the audible clicks telling you that it is working
properly? Which is hardest?
7. Which device is the best size for you to hold in your hand when performing an injection? Which is worst?
8. Which device is the best weight for you to hold in your hand when performing an injection? Which is worst?
9. Which device is the most discreet and easy to carry? Which is worst?
10. Which device is easiest for you to change the cartridge? Which is hardest?
11. Which device is easiest for you to dial back (i.e., if you accidentally dial too much and need to reduce the dose, before
injecting)? Which is hardest?
12. Which would you choose if you were thinking speciﬁcally about how the pen feels to hold, when you inject (e.g., the
weight, the size, the ease of the injection button)? Which would be your last choice?
13. Thinking about all of the different features of these devices that we have discussed today, which device do you think is
easiest to use, overall? Which would be your last choice?
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Table 2 Distribution of participants by country and type of diabetes
Brazil China Egypt India Malaysia Total
Participants recruited, n 100 100 100 100 103 503
Type 1 diabetes 23 25 25 25 8 106
Type 2 diabetes (insulin naı¨ve) 50 51 50 50 48 249
Type 2 diabetes (insulin users) 27 24 25 25 47 148
Current pen (% users)
NovoPen 2 or 3 29
NovoPen 4 38
HumaPen Ergo II 16
HumaPen othera 10








18–30 6 21 28 9 10 84
31–40 24 26 23 49 14 136
41–50 23 33 25 25 27 133
51–60 26 16 19 11 42 114
61–65 7 4 5 4 10 30
65? 4 – – 2 – 6
Participants testing each pen, n
AllStar 99 100 100 80 103
HumaPen Ergo II 89 92 97 71 103
HumaPen Luxura 93 – – – –
NovoPen 4 94 89 83 75 86
Xuilin Pen – 99 – – –
INSUPen – – – 78 –
a Ergo, Savio or Luxura
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participants with AS, 4% with NP4, and 6% with
HE2. In addition, 3% of insulin-naı¨ve
participants struggled with the needle safety
cap with AS and 5% struggled with NP4, both
due to unfamiliarity with the cap.
There were 7–12% of participants who failed
to prime the devices (Step 4); participants
skipping the priming/safety test ranged from
3% (China) to 11% (Egypt) for AS, 4% (Brazil) to
10% (Egypt) for NP4, and 2% (China) to 16%
(Egypt) for HE2. A total of 424 participants
(88%) primed AS, while 397 (93%) primed NP4,
and 407 (90%) primed HE2. Of those who did
prime the devices, 28%, 40%, and 35% had
difficulty priming with AS, NP4, and HE2,
respectively. More than 90% of all problems
were due to misunderstanding of the
methodology required to perform a step, and
were not due to mechanical issues with the pen.
The correct dose (Step 5) was dialed by 90–93%
of participants; 4% of participants dialed an
incorrect dose with each pen, while the
remainder either was unable to dial a dose
(either due to dose button jam or forgetting to
twist/pull out the dose button) or asked which
dose to dial. Most participants delivered the
entire dose (Step 6) with AS (97%), NP4 (93%) or
HE2 (95%), with significantly fewer participants
failing to hold down the button for the required
time with AS (6%), compared with NP4 (22%)
Fig. 1 Ease of use of AllStar, NovoPen 4, and HumaPen Ergo II pens—by steps. AS AllStar, HE2 HumaPen Ergo II, NP4
NovoPen 4
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and HE2 (18%). Most participants knew an
entire dose was delivered because the dose
window read zero (all pens) and/or the dose
button could not be depressed further (AS, NP4,
and HE2) or the clicking sound stopped (NP4
and HE2).
Most Important Features of an Insulin Pen
Participants ranked ease of injecting oneself,
ease of dialing the correct dose, how easy the
device was to use overall, and ease of reading
the dose display as the most important ease-of-
use features of any new insulin pen (Table 3).
Being discreet and easy to carry was ranked as
the least important of the 12 ease-of-use
features. There were no significant differences
between insulin-naı¨ve and current insulin users
in the top four characteristics.
Participants ranked AS highest on nine of 12
key features (Fig. 2), including three of the four
most important features: easiest to use overall
(52%), easiest to read the dose (42%), and
easiest to self-inject (39%). HE2 was ranked
highest for easiest to dial back the dose (47%)
and to feel/hear dial clicks (39%). It was also
ranked highest for easiest to dial the right dose
(36%) but not significantly higher than AS
(35%). Local pens available in Brazil, China,
and India were ranked the lowest for all 12
features. When asked which pen they would
choose, if they were thinking specifically about
how the pen feels to hold when they inject,
54% chose AS compared with 15% for NP4, 23%
for HE2, and 8% for the local pen (P\0.05 for
AS vs. all other pens).
DISCUSSION
The observations from this market research
survey revealed, in a non-clinical setting, how
people with diabetes in the emerging countries
Table 3 Most to least important features of a new insulin pen: by participant preference
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of Brazil, China, Egypt, India, and Malaysia used
the reusable insulin pens available in their
country. Three pens—AS, NP4, and HE2—were
available in all five countries, while an
additional local pen was available in India,
Brazil, and China. Most participants found the
AS, NP4, and HE2 pens easy to use overall, but
with some differences between pens in the
individual steps used to inject a dose. The AS
pen was ranked highest for nine of 12 ease-of-
use features, while HE2 was ranked highest for
two features.
In the first part of the interviews,
participants performed the sequential steps
used to inject a dose of insulin once per pen.
For insulin-naı¨ve participants, this task had the
possibility of being the easiest for the last pen
tried as they learned from the preceding pens.
To reduce this bias, a Latin-squares design was
used to balance the order in which the pens
were introduced. The tasks were followed by a
question-and-answer session to determine the
pen preferences of each participant. This design
has been used in clinical studies involving
insulin pens [4–6] and allows for a comparison
of pen features without any influence from the
insulin therapy. This may mimic clinical
practice for many people with diabetes, where
a diabetes educator or nurse would offer the
person the opportunity to test and choose from
a selection of devices appropriate for the
prescribed insulin regimen. Clinical studies
have evaluated pen devices over an extended
period of actual use with insulin [7–11], and
Fig. 2 Percentage of participants ranking each device in ﬁrst place (globally)
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evaluation of pen features in many of these
studies may have been influenced by the
therapeutic outcome with the pen.
Most people with diabetes who require
insulin self-administer it by subcutaneous
injection, using either a vial and syringe or an
insulin pen device. Worldwide, pen devices are
used by approximately 60% of insulin users,
although usage varies from country to country
[12]. Among the countries involved in the
current study, 95% of people with diabetes in
China are pen users, whereas approximately
60% and 80% use vial and syringe in Brazil and
India, respectively. Compared with vial and
syringe, insulin pens provide better dosing
accuracy, easier dosing and administration,
convenience, increased patient acceptance and
satisfaction; they are also discreet and easily
portable, which lessens social embarrassment
[13–17]. Pens are considered less painful than
syringes and are associated with less needle fear
[17]. Their use is also linked with improved
adherence to insulin therapy and reduced costs
compared with vial and syringe [18], and may
reduce the resistance to starting insulin therapy.
The results provided herein give important
clinical insights into the preferences and usage
capabilities of individuals in regions of the
world where reusable insulin pen availability is
extensive and/or increasing. From a clinical
perspective, the ability of an individual to feel
confident and comfortable with the use of such
a device is an essential factor in enhancing
patient adherence to diabetes management. As
insulin injections are a daily requirement,
recognizing the attributes most desirable to
the patient and providing a device that best
fits those preferences help to ensure seamless
integration of insulin delivery to a patient’s
everyday routine. Additionally, remaining
cognizant of those steps that potentially pose
difficulty with each pen is also important, so
that the diabetes management team (whether
physician, nurse, or caregiver) can focus their
instruction on those steps which may be most
problematic. This holds true for both newly
initiated insulin users (where pen characteristics
may factor in treatment choice) as well as
experienced insulin pen users (for their current
insulin treatment, or if a change in treatment is
considered).
Potential limitations to this study include
first-impression preferences by participants
without long-term, learned pen use, as well as
the inability to gauge comfort and execution of
actual self-injection, particularly for those who
have never utilized insulin. As such, areas of
further research and discussion if data were
available include: (1) influence of age: younger
versus older participants; (2) insulin-naı¨ve
participants versus insulin users; and (3) T1DM
vs. T2DM participants.
CONCLUSIONS
As a result of interviews with individuals with
T1DM or T2DM, it was identified that new and
existing users of insulin pens seek ease of
injection, overall ease of use, and correct dose
delivery as key characteristics for an insulin pen
device. Through hands-on use of these different
pens, priming the reusable insulin pens was the
most difficult aspect of administering a dose;
however, each pen showed slight variation in
the steps that posed difficulty with
administration. The AS pen was easiest to use
overall compared with other reusable pens
tested, and ranked highest by uses in most of
the characteristics identified as most preferred
for a reusable insulin pen. Selection of an
appropriate reusable insulin pen may provide
benefit and comfort for patients starting or
continuing insulin therapy; identifying those
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characteristics that are most preferred by
patients may assist in overcoming barriers to
appropriate dose delivery and overall adherence
with treatment.
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